Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)
We define the pharmacological and pharmacokinetic profiles of a novel α(2C)-adrenoceptor agonist, compound A [N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1,4-benzoxazin-6-yl]-N-ethyl-N'-methylurea]. This compound has high affinity (K(i)) for the human α(2C)-adrenoceptor (K(i) = 12 nM), and 190...
Saved in:
Published in | The Journal of pharmacology and experimental therapeutics Vol. 337; no. 1; pp. 256 - 266 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.04.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We define the pharmacological and pharmacokinetic profiles of a novel α(2C)-adrenoceptor agonist, compound A [N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1,4-benzoxazin-6-yl]-N-ethyl-N'-methylurea]. This compound has high affinity (K(i)) for the human α(2C)-adrenoceptor (K(i) = 12 nM), and 190- to 260-fold selectivity over the α(2A)- and α(2B)-adrenoceptor subtypes. In cell-based functional assays, compound A produced good agonist (EC(50) = 166 nM) and efficacy (E(max) = 64%) responses at the α(2C)-adrenoceptor, much lower potency and efficacy at the α(2A)-adrenoceptor (EC(50) = 1525 nM; E(max) = 8%) and α(2B)-adrenoceptor (EC(50) = 5814 nM; E(max) = 21%) subtypes, and low or no affinity and functional activity at the α(1A)-, α(1B)-, and α(1D)-adrenoceptor subtypes. In the human saphenous vein postjunctional α(2C)-adrenoceptor bioassay, compound A functions as a potent agonist (pD(2) = 6.3). In a real-time contraction bioassay of pig nasal mucosa, compound A preferentially constricted the veins (EC(50) = 108 nM), and the magnitude of arteriolar contraction reached only 50% of the maximum venular responses. Compound A exhibited no effect on locomotor activity, sedation, and body temperature in mice (up to 100 mg/kg) and did not cause hypertension and mydriasis (30 mg/kg) in conscious rats. Compound A is orally bioavailable (24%) with good plasma exposure. This compound is a substrate for the efflux P-glycoprotein transporter, resulting in very low central nervous system (CNS) penetration. In summary, compound A is a highly selective, orally active, and non-CNS-penetrating α(2C)-adrenoceptor agonist with desirable in vitro and in vivo pharmacological properties suitable for the treatment of nasal congestion. |
---|---|
AbstractList | We define the pharmacological and pharmacokinetic profiles of a novel α(2C)-adrenoceptor agonist, compound A [N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1,4-benzoxazin-6-yl]-N-ethyl-N'-methylurea]. This compound has high affinity (K(i)) for the human α(2C)-adrenoceptor (K(i) = 12 nM), and 190- to 260-fold selectivity over the α(2A)- and α(2B)-adrenoceptor subtypes. In cell-based functional assays, compound A produced good agonist (EC(50) = 166 nM) and efficacy (E(max) = 64%) responses at the α(2C)-adrenoceptor, much lower potency and efficacy at the α(2A)-adrenoceptor (EC(50) = 1525 nM; E(max) = 8%) and α(2B)-adrenoceptor (EC(50) = 5814 nM; E(max) = 21%) subtypes, and low or no affinity and functional activity at the α(1A)-, α(1B)-, and α(1D)-adrenoceptor subtypes. In the human saphenous vein postjunctional α(2C)-adrenoceptor bioassay, compound A functions as a potent agonist (pD(2) = 6.3). In a real-time contraction bioassay of pig nasal mucosa, compound A preferentially constricted the veins (EC(50) = 108 nM), and the magnitude of arteriolar contraction reached only 50% of the maximum venular responses. Compound A exhibited no effect on locomotor activity, sedation, and body temperature in mice (up to 100 mg/kg) and did not cause hypertension and mydriasis (30 mg/kg) in conscious rats. Compound A is orally bioavailable (24%) with good plasma exposure. This compound is a substrate for the efflux P-glycoprotein transporter, resulting in very low central nervous system (CNS) penetration. In summary, compound A is a highly selective, orally active, and non-CNS-penetrating α(2C)-adrenoceptor agonist with desirable in vitro and in vivo pharmacological properties suitable for the treatment of nasal congestion. |
Author | Varty, Geoffrey B Shah, Himanshu Boyce, Christopher W McCormick, Kevin D Aslanian, Robert G Lieber, Gisela Jia, Yanlin McLeod, Robbie L Hey, John A Korfmacher, Walter Wu, Jie Feng, Kung-I Rivelli, Maria A Morgan, Cynthia Hunter, John C Nomeir, Amin A Corboz, Michel R Wan, Yuntao Anthes, John C Umland, Shelby Palamanda, Jai |
Author_xml | – sequence: 1 givenname: Michel R surname: Corboz fullname: Corboz, Michel R email: michel.corboz@merck.com organization: In Vivo Pharmacology, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. michel.corboz@merck.com – sequence: 2 givenname: Maria A surname: Rivelli fullname: Rivelli, Maria A – sequence: 3 givenname: Kevin D surname: McCormick fullname: McCormick, Kevin D – sequence: 4 givenname: Yuntao surname: Wan fullname: Wan, Yuntao – sequence: 5 givenname: Himanshu surname: Shah fullname: Shah, Himanshu – sequence: 6 givenname: Shelby surname: Umland fullname: Umland, Shelby – sequence: 7 givenname: Gisela surname: Lieber fullname: Lieber, Gisela – sequence: 8 givenname: Yanlin surname: Jia fullname: Jia, Yanlin – sequence: 9 givenname: Robbie L surname: McLeod fullname: McLeod, Robbie L – sequence: 10 givenname: Cynthia surname: Morgan fullname: Morgan, Cynthia – sequence: 11 givenname: Geoffrey B surname: Varty fullname: Varty, Geoffrey B – sequence: 12 givenname: Jie surname: Wu fullname: Wu, Jie – sequence: 13 givenname: Kung-I surname: Feng fullname: Feng, Kung-I – sequence: 14 givenname: Christopher W surname: Boyce fullname: Boyce, Christopher W – sequence: 15 givenname: Robert G surname: Aslanian fullname: Aslanian, Robert G – sequence: 16 givenname: Jai surname: Palamanda fullname: Palamanda, Jai – sequence: 17 givenname: Amin A surname: Nomeir fullname: Nomeir, Amin A – sequence: 18 givenname: Walter surname: Korfmacher fullname: Korfmacher, Walter – sequence: 19 givenname: John C surname: Hunter fullname: Hunter, John C – sequence: 20 givenname: John C surname: Anthes fullname: Anthes, John C – sequence: 21 givenname: John A surname: Hey fullname: Hey, John A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21233198$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kMtKBDEQRYMovtfuJDsVLM1z0r2UQR1BRhfuRIZ0knEi6aRNd4szv-TKH_GbbHysqg73cKFqB63HFB1CB5ScUcrE-UvjumEbSElVijW0TSWjQCjhW2inbV8IoUKM-CbaYpRxTstiG33cL3SutUkhPXujAzYDa9O57Fe68yniNMcax_TmAv76ZGPQNruYjGu6lLF-TtG3HZ7CIz8VYP1iaXMCAcd0Ar72Vq9SGHAZatctluEE2AToKRZQubhK73rlI4yG-Amm8GPA9Ah-3T47jY9NqpvUR4svTvbQxlyH1u3_zV30cHX5MJ7A7d31zfjiFhopCyjnpKJVqQputVLGKTLcTJUiigtaCEqtI1wSUgnJhC1FoaQ0pWCGlHPOyhHfRUe_tU1Or71ru1ntW-NC0NGlvp0VcmhRrOCDefhn9lXt7KzJvtZ5Oft_L_8Gbv57UA |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1124/jpet.110.175794 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0103 |
EndPage | 266 |
ExternalDocumentID | 21233198 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- -~X .55 .GJ 0R~ 18M 2WC 3O- 4.4 53G 5GY 5RE 5VS 8WZ A6W AAJMC AAYOK ABCQX ABIVO ABJNI ABOCM ABSQV ACGFO ACGFS ACNCT ADBBV ADCOW ADIYS AENEX AERNN AFFNX AFHIN AFOSN AGFXO AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R GX1 H13 HZ~ INIJC KQ8 L7B LSO MJL MVM NPM O9- OHT OK1 P2P R.V R0Z RHF RHI RPT TR2 UQL VH1 W2D W8F WH7 WOQ X7M YBU YHG YQT ZGI ZXP 7X8 AETEA |
ID | FETCH-LOGICAL-p558-9f0b1b9783da77ce70463177073418411de03500b4524d948755c942c09f32963 |
IngestDate | Sat Aug 17 00:39:07 EDT 2024 Sat Sep 28 07:58:08 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p558-9f0b1b9783da77ce70463177073418411de03500b4524d948755c942c09f32963 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 21233198 |
PQID | 858417283 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_858417283 pubmed_primary_21233198 |
PublicationCentury | 2000 |
PublicationDate | 2011-Apr 20110401 |
PublicationDateYYYYMMDD | 2011-04-01 |
PublicationDate_xml | – month: 04 year: 2011 text: 2011-Apr |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of pharmacology and experimental therapeutics |
PublicationTitleAlternate | J Pharmacol Exp Ther |
PublicationYear | 2011 |
SSID | ssj0014463 |
Score | 1.8087405 |
Snippet | We define the pharmacological and pharmacokinetic profiles of a novel α(2C)-adrenoceptor agonist, compound A... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 256 |
SubjectTerms | Adrenergic Agonists - chemistry Adrenergic Agonists - metabolism Adrenergic Agonists - pharmacology Animals CHO Cells Cricetinae Cricetulus Humans Male Methylurea Compounds - chemistry Methylurea Compounds - metabolism Methylurea Compounds - pharmacology Mice Mice, Inbred C57BL Morpholines - chemistry Morpholines - metabolism Morpholines - pharmacology Motor Activity - drug effects Motor Activity - physiology Nasal Mucosa - drug effects Nasal Mucosa - metabolism Rats Rats, Sprague-Dawley Receptors, Adrenergic, alpha-2 - metabolism Recombinant Proteins - agonists Recombinant Proteins - metabolism Saphenous Vein - drug effects Saphenous Vein - metabolism Swine |
Title | Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21233198 https://search.proquest.com/docview/858417283 |
Volume | 337 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB2FsmGDeFNemgUurZIpmfE4jpdpSImgNSxcEYSQ5fEDglJPFRJE8kus-BH-gT_hXtuxnbSIx8aKHM9Ezjmae-bOfRDyOEmcbttRoNxiFcAGxekyBWaSmYrHtiMyzYrRFm5neCJfjKxRo_GzFrU0n6n9cHlhXsn_oAr3AFfMkv0HZMtJ4QZ8BnzhCgjD9a8wfl3Vnc4LfZTVl5elEgyaqf4ST5pGf2AccNFnAeZua4xmwfjJDxpL5zZdZlgHJvzfkkXjj4toqplkWMNpyMan4yhY6gncWEyw4fRiYgiHiSHjiI9kKk6X-iuWqWYdeMSwnjGXZc8x1wBA8jEY_Y5yFmPYsZVTs7dyQnyqCFuTx2fVu-UlotZ6EdTSxspNQV9PlV6ucgHglatDLFjSJ3ke-HEAuFQO3OMQRp0W3eRfgkhIqxDoN7lv-O0cflHXvSPo7i2DauJiRRfoL2mb9SXfzAvNrHG7WMCtTk0LiLwjzHkzIySaGdjXYBrFPkgwO2_VvF7Q233lH54cHfneYORdIpeF7VgYdfp8VEYh4W7cLCpOwaRPN6b8_bYnkz_eNXK1AIb2chJeJ404vUF2CgIuWtSrAdKiO7RGzcVN8m2DqXSTqVQnNKAZU-mP7xsspQVLqcvema06Q3cv5udexs4WPcfN9xUzn9R4SXdXrKS9vVvEOxx4_SEr2oSwM8sCa520FVfowYwC2w5jG2vgcdsG2yV5V3IexXh63lbSEjJycINuhY4UYdtJTAH25zbZSnUa3yU05IEVKvhOBEImijs8kmYs8WQcJ-fbhK7g8GEVxqO1II31_LPfBR2Pnd7MbXInh8k_y6vF-KgNwc517_158H1ypeLwA7I1m87jh6B5Z-pRxppfVROuNQ |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacological+characterization+of+a+novel+%CE%B12C-adrenoceptor+agonist+N-%5B3%2C4-dihydro-4-%281H-imidazol-4-ylmethyl%29-2H-1%2C+4-benzoxazin-6-yl%5D-N-ethyl-N%27-methylurea+%28compound+A%29&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Corboz%2C+Michel+R&rft.au=Rivelli%2C+Maria+A&rft.au=McCormick%2C+Kevin+D&rft.au=Wan%2C+Yuntao&rft.date=2011-04-01&rft.eissn=1521-0103&rft.volume=337&rft.issue=1&rft.spage=256&rft.epage=266&rft_id=info:doi/10.1124%2Fjpet.110.175794&rft.externalDBID=NO_FULL_TEXT |